Sanofi Consumer Healthcare India Limited has informed the Exchange regarding a press release dated May 02, 2025, titled "Announcement under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 Press Release / Media Release".
SANOFICONR · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Sanofi Consumer Healthcare India Limited (SCHIL) announced its Q1 FY2025 results, reporting a Profit After Tax (PAT) of ₹500 million, up 12.9% sequentially compared to Q4 2024. Revenue from operations stood at ₹1,726 million, with EPS rising by ₹2.4 to ₹21.7 per share. The company also launched Allegra D during the quarter, expanding its allergy portfolio. Management noted that Q1 2025 figures are not directly comparable with Q1 2024 due to the demerger from Sanofi India Limited (effective 1st June 2024) and a voluntary product recall of certain key brand variants. SCHIL continues to operate independently, focusing on Allergy, Digestive Wellness, Pain Care, and Multivitamins segments under brands like Allegra, DePURA, Avil, and Combiflam.
Positive sequential earnings growth and a new product launch (Allegra D) signal steady business momentum post-demerger, though the lack of year-on-year comparability may limit direct historical benchmarking for investors.